Ceftriaxone

Mechanism of action

Ceftriaxone is a time-dependent β-lactam antibiotic that irreversibly inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP1a and PBP1b. This disrupts cross-linking of peptidoglycan and causes cell wall instability and lysis. Unlike aminoglycosides, ceftriaxone shows minimal post-antibiotic effect, and efficacy depends on the percentage of time serum concentration exceeds the minimum inhibitory concentration (MIC). It has excellent penetration into the central nervous system, achieving 10–30% of serum levels in uninflamed meninges and up to 80% when meninges are inflamed—critical for meningitis coverage.

Indications

• Bacterial meningitis (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae)
• Gonorrhea (including cephalosporin-resistant N. gonorrhoeae; now often combined with azithromycin or doxycycline per CDC guidance)
• Lyme disease (early disseminated or late neurologic disease)
• Serious Gram-negative infections (E. coli, Klebsiella, Proteus, Enterobacter, Serratia, Citrobacter)
• Gram-positive infections (penicillin-susceptible and intermediate S. pneumoniae, Group B Streptococcus)
• Acute bacterial arthritis and osteomyelitis
• Endocarditis (as part of combination therapy)
• Intra-abdominal infections (in combination with metronidazole for anaerobic coverage including Bacteroides fragilis)
• Prophylaxis in cardiac surgery and high-risk patients
• PID and pelvic inflammatory disease (in combination regimens)

Pharmacokinetics

Absorption: Ceftriaxone is not orally bioavailable; administered IV or IM.

Distribution: Widely distributed. Excellent CNS penetration (10–30% of serum in uninflamed meninges; up to 80% with meningeal inflammation). Protein binding ~83–96%. Crosses placenta and enters breast milk in low concentrations.

Metabolism: Minimal hepatic metabolism; ceftriaxone is excreted unchanged in urine (~60%) and bile (~40%).

Elimination: Half-life is 5.8–8.7 hours, permitting once or twice daily dosing. Renal clearance is the primary route; biliary excretion is significant.

Special populations: No dose adjustment typically needed for mild-to-moderate renal impairment; however, use with caution in severe renal disease. Hepatic disease does not significantly affect clearance. Elderly patients may have reduced renal clearance but standard dosing is usually appropriate.

Adverse effects

Common:

• Diarrhea and Clostridioides difficile infection (CDI)
• Local reactions at injection site (phlebitis, pain)
• Rash (maculopapular, urticarial)

Serious:

• Hypersensitivity reactions including anaphylaxis (1–3% cross-reactivity with penicillins; caution in penicillin allergy)
• Biliary pseudolithiasis (reversible ceftriaxone-calcium precipitate in bile; can mimic cholelithiasis; more common in children; resolves on discontinuation)
• Hypoprothrombinemia and bleeding (mild, related to suppression of vitamin K-producing flora; rare clinically significant bleeding)
• Hemolytic anemia (rare; usually Coombs-positive)
• Stevens-Johnson syndrome / Toxic epidermal necrolysis (rare but serious)
• Seizures (rare; higher risk in renal impairment or meningitis)
• Hepatotoxicity (transient elevation in liver enzymes; fulminant hepatitis rare)
• Nephrotoxicity (rare at standard doses; risk increases with other nephrotoxic agents or renal disease)

Important: Ceftriaxone-calcium chelation complex can precipitate in IV lines and cause thrombophlebitis or, rarely, necrotizing enterocolitis in neonates (do not co-infuse with calcium solutions).

Contraindications and warnings

Contraindications:

• True IgE-mediated penicillin allergy (use with extreme caution; consider allergy evaluation)
• Cephalosporin allergy
• Neonatal period: avoid simultaneous administration with IV calcium due to risk of precipitation and necrotizing enterocolitis

Black box warnings: None; however, serious cautions include:

Warnings:

• Severe renal impairment: Use with caution; monitor renal function and consider dose adjustment or extended intervals if creatinine clearance <30 mL/min
• Hepatic disease: Unlikely to require adjustment but use cautiously
• Meningitis: High doses are needed; ceftriaxone achieves therapeutic CNS levels only with adequate dosing (2 g IV Q12H or higher)
• Biliary pseudolithiasis: Monitor for abdominal pain or imaging findings in prolonged therapy; usually reversible
• Pseudomembranous colitis: Risk of CDI; use lowest effective dose and duration
• Hypoprothrombinemia: Assess baseline coagulation in high-risk patients; vitamin K supplementation may be considered
• Pregnancy: FDA pregnancy category B (older classification); generally considered safe; used in meningitis and other serious infections in pregnant women
• Breastfeeding: Ceftriaxone is excreted in breast milk in low amounts; generally considered compatible

Drug interactions

• Warfarin: May potentiate anticoagulation via reduction of vitamin K-producing flora; monitor INR
• Probenecid: Reduces renal clearance of ceftriaxone; not typically co-administered
• Calcium: Do NOT co-infuse IV ceftriaxone with IV calcium-containing solutions (risk of precipitation, thrombophlebitis, or necrotizing enterocolitis in neonates); separate administration by at least 48 hours or use different lines
• Oral anticoagulants: Enhanced anticoagulant effect; monitor coagulation parameters
• Methotrexate: Potential for reduced methotrexate clearance and toxicity; use with caution
• Aminoglycosides: Synergistic activity but no pharmacokinetic interaction; monitor renal function
• Other β-lactams: No major interactions; may be used in combination for synergy
• Alcohol: No significant interaction

Clinical pearls

• Meningitis dosing: Requires high doses (2 g IV Q12H or sometimes higher) to achieve adequate CSF penetration; standard dosing is insufficient
• Gonorrhea: CDC's recommendation now favors ceftriaxone 500 mg IM × 1 plus additional agent (e.g., doxycycline or azithromycin) due to emerging resistance
• Lyme disease: Third-generation cephalosporin of choice for early disseminated or late-stage neurologic disease (neuroborreliosis, acrodermatitis chronica atrophicans)
• Biliary pseudolithiasis: Ultrasound may show echogenic material or sludge in the gallbladder; distinguish from true stones by clinical correlation and repeat imaging post-therapy
• Once daily vs twice daily: Both regimens are effective; Q12H dosing is standard for serious infections and meningitis; Q24H may be used for less severe infections depending on organism MIC
• Beta-lactam allergy history: Obtain detailed allergy history (rash vs anaphylaxis); true IgE-mediated anaphylaxis warrants avoidance; non-IgE rashes may allow use with close monitoring
• Seizure risk: Rare but increased in renal impairment or CNS infection; maintain adequate dosing and consider prophylaxis if history of seizures
• Vitamin K production: Long courses (>2 weeks) may warrant vitamin K supplementation, especially in elderly or malnourished patients
• Third-generation advantage: Superior Gram-negative coverage and CNS penetration compared to first and second-generation cephalosporins; reserved for serious infections
• Anaerobic coverage: Ceftriaxone lacks reliable activity against Bacteroides fragilis and other clinically important anaerobes; must be combined with metronidazole or similar antianaerobic agents for intra-abdominal or mixed anaerobic infections

Practice questions

Frequently asked questions

Conditions it is used for

Related drugs

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J01DD04

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.